Lead Product(s): AUT00206
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AUT00206
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $50.1 million Upfront Cash: $29.5 million
Deal Type: Termination August 26, 2020
Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.